Published in Arch Roum Pathol Exp Microbiol on December 01, 1976
Mouse alpha-macroglobulin. Structure, function and a molecular model. Biochem J (1987) 0.79
Hemin-deficient mutants of Escherichia coli K-12. J Bacteriol (1968) 2.69
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol (1999) 1.35
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol (1999) 1.15
Repair of single-stranded DNA nicks, gaps, and loops in mammalian cells. Mol Cell Biol (1987) 1.13
Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol (2001) 1.10
[The effect of products of plant and microbial origin on phagocytic function and on the release of oxygen free radicals by mouse peritoneal macrophages]. Bacteriol Virusol Parazitol Epidemiol (1997) 1.09
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 1.09
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol (1999) 1.06
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol (1996) 1.06
Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience (2008) 1.05
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol (1998) 1.04
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem (2001) 1.02
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 1.02
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol (2001) 1.02
In vitro stimulatory effect of substance P on hematopoiesis. Blood (1993) 1.01
Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol (2000) 1.00
ELISA in the Q fever diagnosis. Arch Roum Pathol Exp Microbiol (1984) 0.98
Expression of caveolae on the surface of rat arterial smooth muscle cells is dependent on the phenotypic state of the cells. Lab Invest (1997) 0.95
Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci (2000) 0.94
Transcription termination within the Escherichia coli origin of DNA replication, oriC. Mol Gen Genet (1986) 0.94
Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase, and transcription factors NFkappaB and AP-1. Cardiovasc Res (2000) 0.91
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem (1999) 0.91
Dpp and Hh signaling in the Drosophila embryonic eye field. Development (2001) 0.89
An alpha2-macroglobulin associated factor produced by T lymphocytes which provides polyclonal stimulation of B lymphocytes to maintain the turnover of their surface Ig. Immunology (1981) 0.89
Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol (1993) 0.89
VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol (1998) 0.88
Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72. Am J Physiol Heart Circ Physiol (2000) 0.87
Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem (2001) 0.87
VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci (2000) 0.86
Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol (1997) 0.86
Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol (2000) 0.85
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J Immunol (2000) 0.85
Effect of serum alpha2-macroglobulin on the trypsin-soybean trypsin inhibitor complex. Arch Roum Pathol Exp Microbiol (1975) 0.84
Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6. J Immunol (1994) 0.84
VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann N Y Acad Sci (2000) 0.84
Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol (1996) 0.84
Degradation of a chromogenic substrate by alpha 2-macroglobulin from plasma of patients with rheumatoid arthritis. Arthritis Rheum (1984) 0.84
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol (1996) 0.84
Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol (1993) 0.84
Polyclonal B-cell activator with esterolytic activity and polyclonal gammopathy induced by allogeneic cells in rabbits. Immunology (1982) 0.83
Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regul Pept (1997) 0.83
VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol (1999) 0.83
Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage. Free Radic Res (2000) 0.83
The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol (2000) 0.83
Extrachromosomal eukaryotic DNA substrates for switch recombination: analysis of isotype and cell specificity. DNA Cell Biol (1994) 0.83
Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol (1999) 0.82
Role of tyrosine kinases in extracellular matrix-mediated modulation of arterial smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (1997) 0.82
VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann N Y Acad Sci (1999) 0.82
Blast transformation of B cells induced by an alpha-macroglobulin-associated lymphokine produced in crowded lymphoid cell cultures. J Immunol (1983) 0.81
Species-specific activity of rat recombinant interleukin-1 beta. J Interferon Cytokine Res (1995) 0.81
TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem (2001) 0.81
Immunoregulatory effects of neuropeptides. Stimulation of interleukin-2 production by substance p. J Neuroimmunol (1992) 0.81
VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. Arch Physiol Biochem (2001) 0.80
Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life (2010) 0.80
Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J Neuroimmunol (1994) 0.80
Effects of calcium blockers on the cytosolic calcium, H2O2 production and elastase release in human neutrophils. Pharmacol Toxicol (1996) 0.79
Introduction to the study of adult T-cell leukemia and HTLV-I sero-positivity in Romania. Rom J Intern Med (1994) 0.79
The migratory and phagocytic activity of polymorphonuclear leukocytes in rheumatoid arthritis and osteoarthritis patients. Roum Arch Microbiol Immunol (2002) 0.79
VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells. J Neuroimmunol (2001) 0.79
The effect of protease inhibitors on the polyclonal B cell activator from the serum of patients with rheumatoid arthritis. Int J Immunopharmacol (1982) 0.79
VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann N Y Acad Sci (1998) 0.78
Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann N Y Acad Sci (1996) 0.78
Modulation of IgG effector functions by a monovalent fragment of staphylococcal protein A. Mol Immunol (1986) 0.78
Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia. Ann N Y Acad Sci (2000) 0.78
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J Immunol (2000) 0.78
Procain and diethylaminoethanol influence on the release of free oxygen radicals by polymorphonuclear leukocytes, in rabbits and humans. Roum Arch Microbiol Immunol (1998) 0.78
The in vitro action of a succussed substance on the proliferative response of human lymphocytes stimulated with phytohemagglutinin. Rom J Intern Med (1992) 0.77
The protective activity of murine and human alpha 2-macroglobulin on the lethally irradiated mice. Arch Roum Pathol Exp Microbiol (1980) 0.77
Shift toward T lymphocytes with Th1 and Tc1 cytokine-secterion profile in the joints of patients with osteoarthritis. Roum Arch Microbiol Immunol (2002) 0.76
Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. J Neuroimmunol (2000) 0.76
The effect of alpha-fetoprotein on the immune response. III. Diminution of the phagocytic capacity of macrophages cultures in vitro in the presence of mouse amniotic fluid or alpha-fetorprotein. Arch Roum Pathol Exp Microbiol (1978) 0.76
Allogeneic lymphocyte stimulation in rabbits: induction of a low MW inhibitor for trypsin and for a concurrently induced alpha-macroglobulin-proteinase complex. Immunology (1985) 0.76
A low molecular weight proteinase inhibitor produced by T lymphocytes. Immunology (1986) 0.76
Expression of NK-1 receptor mRNA in murine T lymphocytes. Neuroimmunomodulation (1997) 0.76
Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. J Interferon Cytokine Res (1995) 0.76
Correlation between the triggering of proliferation and the potentiation of NK activity induced by protein A in human lymphocytes. Immunol Lett (1983) 0.76
Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regul Pept (1999) 0.75
ELISA for toxinogenesis identification in Corynebacterium diphtheriae, diagnostic value. Arch Roum Pathol Exp Microbiol (1986) 0.75
[The localization of alpha-fetoprotein in the mouse fetus by immunofluorescence and immunodiffusion tests]. Arch Roum Pathol Exp Microbiol (1989) 0.75
Epurox in the treatment of juvenile rheumatoid arthritis. Rev Med Chir Soc Med Nat Iasi (1987) 0.75
Inhaled budesonide regimen enhances serotonin- and arachidonic acid-induced platelet aggregation. Agents Actions (1992) 0.75
[Blast study in acute leukemia using monoclonal antibodies]. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna (1988) 0.75
[Influencing of the maternal and fetal acid-base equilibrium through labor under analgesia]. Arch Gynakol (1971) 0.75
Does alpha-fetoprotein influence the immune response? Arch Roum Pathol Exp Microbiol (1980) 0.75
Phenotypic and functional changes in chronic lymphocytic leukemia. Rom J Intern Med (1994) 0.75
The relationship between aminoaciduria and plasma hemoglobin levels. Rom J Intern Med (1994) 0.75
The effect of alpha-fetoprotein on the immune response. IV. Effect of treatment with alpha-fetoprotein on mice infected with bacteria in various experimental conditions. Arch Roum Pathol Exp Microbiol (1979) 0.75
[On the interrelations between chronic hepatopathies and diabetes mellitus]. Med Interna (Bucur) (1971) 0.75
Histochemistry of the epimerases 3. Uridine diphosphogalactose-4-epimerase. Histochemie (1968) 0.75
Serum immunoglobulins in middle and old age dementia. Neurol Psychiatr (Bucur) (1980) 0.75
Micronucleus test applied in patients with acute leukemia, before and at different intervals during the cytostatic treatment. Morphol Embryol (Bucur) (1989) 0.75